Management of Relapsed/Refractory Metastatic Melanoma

Source: OncLive, September 2019

Sanjiv S. Agarwala, MD: Perfect segue to talk about the resistant patients. Let’s start with the patient who has been on BRAF/MEK therapy and then they becomes resistant, now or later. Resistance, of course, is a very complicated issue. What is your approach to that patient? Obviously, you would continue immunotherapy, it’s a little easier. But what if the patient is BRAF wild-type, then it becomes a much better …..

Caroline Robert, MD, PhD: Usually you are very happy when you have a clinical trial and …. you can enroll your patients because otherwise you don’t have a lot of choices, and you’re back to chemotherapy sometimes. Usually the patients say, oh, chemotherapy doesn’t work, I don’t want it.

Sanjiv S. Agarwala, MD: Everyone has anecdotes, right, of chemotherapy working very well after, in 1 or 2 patients after immunotherapy.